Acadia Pharmaceutica (ACAD)

$26.46 -0.13 (-0.49%)
Market Cap 4.50B
Revenue (ttm) 957.80M
Net Income (ttm) 226.45M
EPS (ttm) N/A
PE Ratio 38.26
Forward PE 38.66
Profit Margin 23.64%
Debt to Equity Ratio 0.00
Volume 1,140,900
Avg Vol 1,471,248
Day's Range N/A - N/A
Shares Out 169.18M
Stochastic %K 41%
Beta 0.68
Analysts Strong Sell
Price Target $30.16

Company Profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimava...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 558 2871
Fax: 858 212 0513
Address:
12830 El Camino Real, Suite 400, San Diego, United States
zeustony88
zeustony88 Jan. 13 at 7:10 PM
$ACAD "Top-line results from the Phase 2 RADIANT study of remlifanserin (formerly ACP‑204) in Alzheimer’s disease psychosis (ADP), expected in the August to October 2026 timeframe." "Remlifanserin expected to account for approximately $4 billion of the $11 billion unadjusted full peak sales opportunity represented by its current pipeline, attributable to remlifanserin in both Alzheimer’s disease psychosis and Lewy body dementia psychosis." Gamechanger
0 · Reply
BearTamerTrading
BearTamerTrading Jan. 11 at 11:56 PM
On Watch for JPM Week: Part 1 $JNJ – Johnson & Johnson – presenting at the conference on Jan 12, 2026. $ACAD – Acadia Pharmaceuticals – presenting on Jan 13, 2026. $ONC – BeOne Medicines Ltd. – presenting on Jan 13, 2026. $NUVL – Nuvalent, Inc. – presenting on Jan 13, 2026. $ARWR – Arrowhead Pharmaceuticals – scheduled to present on Jan 12, 2026.
0 · Reply
SBL71
SBL71 Jan. 9 at 2:41 PM
$ACAD Uli Hacksell.
1 · Reply
raylin
raylin Jan. 6 at 8:29 PM
$ACAD Finally having some recovery.
0 · Reply
Intelgod1992
Intelgod1992 Dec. 31 at 3:03 PM
$ACAD $KPTI $SAGE $VNDA
0 · Reply
OvernightSwingKing
OvernightSwingKing Dec. 31 at 2:59 PM
$VNDA Anything under $10 is robbery… Once we cross $10, you will never see a single digit entry again!! $12-$15 EOD $SAGE $ACAD $KPTI
0 · Reply
OvernightSwingKing
OvernightSwingKing Dec. 31 at 2:46 PM
$ACAD $AXSM $KPTI $VNDA 😃
0 · Reply
OvernightSwingKing
OvernightSwingKing Dec. 31 at 11:20 AM
$VNDA Double digits coming here imo… This is huge news!!! $AXSM $KPTI $ACAD
1 · Reply
GLPHOTOX
GLPHOTOX Dec. 29 at 12:18 AM
$ACAD so 2026 is almost here, what are your favorite 3 stock pics for 2026 ?
1 · Reply
SBL71
SBL71 Dec. 26 at 10:35 PM
$ACAD on to 2026. The re-set year. Get us back in the 30’s by 2Q this time next year 45-50.
0 · Reply
Latest News on ACAD
ACADIA Pharmaceuticals Inc. (ACAD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 4:05 PM EST - 13 hours ago

ACADIA Pharmaceuticals Inc. (ACAD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 9:00 AM EST - 20 hours ago

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Dec 18, 2025, 4:05 PM EST - 26 days ago

Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

Dec 12, 2025, 8:00 AM EST - 4 weeks ago

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality

Dec 4, 2025, 6:26 PM EST - 5 weeks ago

Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 2, 2025, 1:23 PM EST - 6 weeks ago

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

Nov 20, 2025, 4:05 PM EST - 7 weeks ago

Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

ACADIA Pharmaceuticals Inc. (ACAD) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 4:31 PM EST - 2 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Presents at UBS Global Healthcare Conference 2025 Transcript

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:36 AM EST - 2 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call Transcript

Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

Nov 5, 2025, 4:05 PM EST - 2 months ago

Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Oct 28, 2025, 4:05 PM EDT - 2 months ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 22, 2025, 3:41 PM EDT - 2 months ago

Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights

Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025

Oct 15, 2025, 4:05 PM EDT - 3 months ago

Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025

ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish

Oct 6, 2025, 7:30 AM EDT - 3 months ago

ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Oct 2, 2025, 9:04 AM EDT - 3 months ago

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short

Sep 24, 2025, 10:05 AM EDT - 3 months ago

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short

Acadia Pharmaceuticals' rare disease therapy fails late-stage trial

Sep 24, 2025, 7:12 AM EDT - 3 months ago

Acadia Pharmaceuticals' rare disease therapy fails late-stage trial

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

Sep 24, 2025, 7:00 AM EDT - 3 months ago

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

Sep 12, 2025, 4:05 PM EDT - 4 months ago

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 8, 2025, 4:05 PM EDT - 4 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 4:04 PM EDT - 4 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

Aug 25, 2025, 4:05 PM EDT - 5 months ago

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 3:57 AM EDT - 5 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

Aug 6, 2025, 4:05 PM EDT - 5 months ago

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 5, 2025, 4:05 PM EDT - 5 months ago

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

Aug 4, 2025, 4:05 PM EDT - 5 months ago

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In

Jul 28, 2025, 4:32 AM EDT - 6 months ago

Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025

Jul 23, 2025, 4:05 PM EDT - 6 months ago

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

Jun 25, 2025, 8:00 AM EDT - 7 months ago

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Jun 9, 2025, 4:01 PM EDT - 7 months ago

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

Jun 5, 2025, 9:05 AM EDT - 7 months ago

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 29, 2025, 4:05 PM EDT - 8 months ago

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

May 27, 2025, 4:05 PM EDT - 8 months ago

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

May 19, 2025, 8:25 AM EDT - 8 months ago

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

May 17, 2025, 10:00 AM EDT - 8 months ago

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation

May 16, 2025, 1:43 PM EDT - 8 months ago

Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation

ACADIA Pharmaceuticals: Advancing On Several Fronts

May 13, 2025, 12:01 PM EDT - 8 months ago

ACADIA Pharmaceuticals: Advancing On Several Fronts

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript

May 7, 2025, 8:10 PM EDT - 8 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

May 7, 2025, 4:05 PM EDT - 8 months ago

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

May 5, 2025, 4:05 PM EDT - 9 months ago

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

Apr 23, 2025, 4:05 PM EDT - 9 months ago

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Mar 5, 2025, 9:05 AM EST - 11 months ago

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

Mar 3, 2025, 9:05 AM EST - 11 months ago

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

Acadia Pharmaceuticals Ends FY2024 On Solid Footing

Mar 2, 2025, 5:19 AM EST - 11 months ago

Acadia Pharmaceuticals Ends FY2024 On Solid Footing

Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference

Feb 27, 2025, 4:05 PM EST - 11 months ago

Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 8:13 PM EST - 11 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Feb 26, 2025, 4:05 PM EST - 11 months ago

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Feb 12, 2025, 4:05 PM EST - 11 months ago

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Jan 14, 2025, 9:05 AM EST - 1 year ago

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

zeustony88
zeustony88 Jan. 13 at 7:10 PM
$ACAD "Top-line results from the Phase 2 RADIANT study of remlifanserin (formerly ACP‑204) in Alzheimer’s disease psychosis (ADP), expected in the August to October 2026 timeframe." "Remlifanserin expected to account for approximately $4 billion of the $11 billion unadjusted full peak sales opportunity represented by its current pipeline, attributable to remlifanserin in both Alzheimer’s disease psychosis and Lewy body dementia psychosis." Gamechanger
0 · Reply
BearTamerTrading
BearTamerTrading Jan. 11 at 11:56 PM
On Watch for JPM Week: Part 1 $JNJ – Johnson & Johnson – presenting at the conference on Jan 12, 2026. $ACAD – Acadia Pharmaceuticals – presenting on Jan 13, 2026. $ONC – BeOne Medicines Ltd. – presenting on Jan 13, 2026. $NUVL – Nuvalent, Inc. – presenting on Jan 13, 2026. $ARWR – Arrowhead Pharmaceuticals – scheduled to present on Jan 12, 2026.
0 · Reply
SBL71
SBL71 Jan. 9 at 2:41 PM
$ACAD Uli Hacksell.
1 · Reply
raylin
raylin Jan. 6 at 8:29 PM
$ACAD Finally having some recovery.
0 · Reply
Intelgod1992
Intelgod1992 Dec. 31 at 3:03 PM
$ACAD $KPTI $SAGE $VNDA
0 · Reply
OvernightSwingKing
OvernightSwingKing Dec. 31 at 2:59 PM
$VNDA Anything under $10 is robbery… Once we cross $10, you will never see a single digit entry again!! $12-$15 EOD $SAGE $ACAD $KPTI
0 · Reply
OvernightSwingKing
OvernightSwingKing Dec. 31 at 2:46 PM
$ACAD $AXSM $KPTI $VNDA 😃
0 · Reply
OvernightSwingKing
OvernightSwingKing Dec. 31 at 11:20 AM
$VNDA Double digits coming here imo… This is huge news!!! $AXSM $KPTI $ACAD
1 · Reply
GLPHOTOX
GLPHOTOX Dec. 29 at 12:18 AM
$ACAD so 2026 is almost here, what are your favorite 3 stock pics for 2026 ?
1 · Reply
SBL71
SBL71 Dec. 26 at 10:35 PM
$ACAD on to 2026. The re-set year. Get us back in the 30’s by 2Q this time next year 45-50.
0 · Reply
MicroMaven
MicroMaven Dec. 26 at 2:32 PM
$ACAD Price action signals that reliability now matters more than headline momentum. Efficiency initiatives must translate into measurable productivity. Overextension would degrade optionality during downturns. Without validation, volatility will remain persistent.
1 · Reply
Doozio
Doozio Dec. 24 at 12:02 AM
$ACAD bahht they wull EXEL because only da 🐑 will be shook ENTA 🐒🍌🧠⏰♾️. New all timers barrring a faatch 💣 in 2026
0 · Reply
StockConsultant
StockConsultant Dec. 22 at 3:51 PM
$ACAD Acadia Pharmaceuticals stock with a bull flag breakout
0 · Reply
dgbio
dgbio Dec. 20 at 3:06 AM
$ACAD 'Real-world use of trofinetide: a survey of practices from prescribers: • Most respondents (95%, n = 21) indicated they titrate trofinetide and 86% (n = 19) believed titration improved tolerability. • Respondents estimated a median 75% of patients achieve their label dose after titration. • Respondents encourage families to remain on trofinetide for a median of ≥16 weeks to adequately evaluate efficacy; most (77%, n = 17) indicated this period should start after the patient arrives at their highest tolerable dose'. https://www.tandfonline.com/doi/full/10.1080/23995270.2025.2597031?src=#abstract
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 19 at 4:08 PM
$ABR $ABT $ABVX $ACA $ACAD
0 · Reply
zeustony88
zeustony88 Dec. 19 at 2:51 PM
$ACAD $28 today?
1 · Reply
JFDI
JFDI Dec. 19 at 2:00 PM
$ACAD 3wt at high end range
0 · Reply
This_Bull_Is_Retired
This_Bull_Is_Retired Dec. 18 at 11:08 AM
$ACAD
0 · Reply
SBL71
SBL71 Dec. 17 at 5:32 PM
$ACAD
0 · Reply
Quantumup
Quantumup Dec. 17 at 1:45 PM
Citizens $TSHA Market Outperform/$8 $NGNE $NVS $ACAD AVXL $ALPMY Citizens said—Taysha (TSHA, MO, $8 PT) and Neurogene (NGNE, NC) are moving into registrational studies and both show significant promise. Both registrational studies are well-designed, according to Dr. Davies, to capture improvements in clinical benefit and leverage primary outcomes that are objective measurements of performance outcomes and not patient/caregiver reported or effort based, which are less meaningful.
1 · Reply
This_Bull_Is_Retired
This_Bull_Is_Retired Dec. 17 at 12:23 PM
$ACAD Braidwell just picked up 2.78 million shares on 11-14 and Frazier picked up 613 K shares. What do they know that we do not? BTW, I sold my shares years ago right before the steep decline thanks to the FAKE FDA! Is this still considered a BO Canidate?
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 4:00 PM
HC Wainwright & Co. has updated their rating for ACADIA Pharmaceuticals ( $ACAD ) to Buy with a price target of 37.
0 · Reply